Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study

BMC Public Health

Table 2 Observed and need-standardized incidence of statin treatment among asymptomatic individuals, according to gender, age-group and SEP indicators

Gender	SEP	40-54			55-64			65-74			75-84
		Need	Statin incidence^d		Need	Statin incidence		Need	Statin incidence		Need	Statin incidence
	INCOME^a	Weight^c	Observed	St.dized^e	Weight	Observed	St.dized	weight	Observed	St.dized	weight	Observed	St.dized
Male	1 (Low)	1.00	8.0	8.0	1.00	16.0	16.0	1.00	18.6	18.6	1.00	10.2	10.2
	2	0.90	9.0	10.0	1.01	19.1	18.9	0.96	22.2	23.2	0.81	10.9	13.5
	3	0.91	9.8	10.7	0.90	20.3	22.5	0.89	23.3	26.1	0.85	11.2	13.2
	4	0.82	10.2	12.4	0.80	21.2	26.4	0.79	23.2	29.3	0.77	12.6	16.3
	5 (High)	0.71	10.5	14.9	0.70	21.3	30.5	0.65	23.4	35.8	0.66	15.0	22.8
Female	1 (Low)	1.00	8.3	8.3	1.00	23.5	23.5	1.00	28.2	28.2	1.00	14.1	14.1
	2	0.80	8.3	10.4	0.85	25.2	29.8	0.85	29.4	34.6	0.90	15.3	17.1
	3	0.64	8.4	13.1	0.64	24.7	38.8	0.90	28.8	32.0	1.02	15.6	15.3
	4	0.60	8.5	14.1	0.57	23.1	40.5	0.69	29.2	42.0	0.82	17.7	21.6
	5 (High)	0.49	7.6	15.6	0.31	20.7	67.0	0.44	28.2	63.4	0.64	17.5	27.5
	EDUCATION ^b
Male	1 (Basic)	1.00	9.4	9.4	1.00	18.7	18.7	1.00	20.5	20.5	1.00	11.6	11.6
	2	0.81	10.2	12.6	0.89	20.6	23.2	0.97	23.9	24.6	0.94	14.6	15.6
	3	0.59	8.3	14.1	0.75	18.5	24.6	0.82	22.1	27.0	0.76	13.9	18.2
	4 (High)	0.50	8.8	17.8	0.66	19.9	30.2	0.65	23.8	36.7	0.72	15.7	21.8
Female	1 (Basic	1.00	9.9	9.9	1.00	25.6	25.6	1.00	28.9	28.9	1.00	17.3	17.3
	2	0.63	8.8	14.0	0.68	23.8	35.2	0.79	30.0	38.1	0.82	20.2	24.7
	3	0.43	6.0	14.0	0.47	18.7	39.6	0.54	25.2	46.3	0.68	17.2	25.3
	4 (High)	0.34	6.2	18.2	0.38	19.1	50.8	0.53	26.4	50.2	0.65	19.0	29.5

a) Quintiles of disposable family income within gender and 5-years age-groups – inflated average over 1996–2001.
b) Educational levels, cf. notes in Table 1.
c) Incidence Rate Ratio of myocardial infarction (MI-IRR) among asymptomatic individuals, applying lowest SEP group (within gender and age-group) as reference group.
d) Incidence of statin therapy among asymptomatic individuals: 1000*(Number incident statin dispensing/person years at risk).
e) Need-standardized statin incidence (‘St.dized’): Observed statin incidence/MI-IRR.

ISSN: 1471-2458